Ideaya Biosciences selects Werner Helicase Inhibitor Development DC with GSK

Ideaya Biosciences (IDYA) announced selection of a Werner Helicase Inhibitor Development Candidate, or DC, and Investor R&D Day. The Werner Helicase Inhibitor DC is a potent, selective, small molecule inhibitor of the helicase domain of Werner protein. Ideaya is collaborating with GSK on IND-enabling studies to support the clinical evaluation of the Werner Helicase Inhibitor DC for patients having tumors characterized by high microsatellite instability, or MSI-High. There is high prevalence of MSI-High across multiple solid tumor indications, including endometrial, colorectal, and gastric cancers, among others. Ideaya and GSK (GSK) are collaborating on the ongoing IND-enabling studies and GSK will lead clinical development for the Werner Helicase program. GSK is responsible for 80% of global research and development costs and Ideaya is responsible for 20% of such costs. GSK holds a global, exclusive license to develop and commercialize the Werner Helicase Inhibitor DC. Ideaya earned a $3M milestone from GSK in connection with IND-enabling studies and has the potential to earn up to an additional $17M aggregate milestone payments through early Phase 1. Ideaya will also be eligible to receive additional future aggregate total development milestones of up to $465M. Upon commercialization, Ideaya will be eligible to receive up to $475M of commercial milestones, 50% of U.S. net profits and tiered royalties on global non-U.S. net sales of the Werner Helicase Inhibitor DC – ranging from high single-digit to sub-teen double-digit percentages, subject to certain customary reductions.